The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated...
Hence then, the article about hansa biopharma submits bla to fda for imlifidase in desensitization for kidney transplantation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation )
Also on site :
- FIFA’s plan to raise billions from investors is sparking a backlash—one insider says Europe is angry because it could change soccer’s balance of power
- Monroe County committees vote to accept $160,000 Operation Stonegarden border security grant despite opposition
- Doc Talk Podcast: Director Sara Dosa On Her Oscar Contender ‘Time And Water’, Elegy For Iceland’s Disappearing Ice